Information about SaveRxCanada.to
List of countries where we can ship Blonanserin:
Latest news releases on Blonanserin:
Blonanserin has a relatively high affinity towards the 5-HT 6 receptor perhaps underpinning its recently unveiled efficacy in treating the cognitive symptoms of schizophrenia. The efficacy of blonanserin can in part be attributed to its chemical structure, which is unique from those of other atypical antipsychotics.
Blonanserin | C23H30FN3 | CID 125564 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety ...
Blonanserin produced significant reductions from baseline in the BPRS total score (P < 0.001). In summary, these data suggest that blonanserin may have long-term efficacy for the treatment of schizophrenia. However, data on direct head-to-head comparison with other antipsychotics are lacking for the maintenance treatment of the illness.
Blonanserin is a D2/5-HT2 receptor antagonist; atypical antipsychotic. Features and Benefits This compound was developed by Dainippon Sumitomo. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Blonanserin is a medicine available in a number of countries worldwide. A list of US medications equivalent to Blonanserin is available on the Drugs.com website.
ブロナンセリン (Blonanserin) は、大日本住友製薬が開発した非定型抗精神病薬の一種である。統合失調症の治療薬として用いられる。 効能・効果は「統合失調症」とされている 。 日本では、2008年4月より商品名ロナセンで販売され、後発医薬品も存在する。
Abstract. Oral blonanserin (Lonasen®) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomized and noncomparative trials.
Of the 117 patients in cohort 1, 108 were treated with blonanserin tablets, and 97 received blonanserin patches and were included in the safety analysis set. In cohort 2, 103 of the 106 patients were treated with blonanserin transdermal patches and were included in the safety analysis set. In total, 91 patients were male (45.5%).
Blonanserin was approved by Pharmaceuticals and Medical Devices Agency of Japan (PMDA) on January 25, 2008. It was developed and marketed as Lonasen ® by Dainippon Sumitomo Pharma in JP. Blonanserin acts as a mixed 5-HT 2A (K i =0.812 nM) and D 2 receptor (K i =0.142 nM) antagonist and also exerts some blockade of α 1-adrenergic receptors (K ...
Blonanserin je organsko jedinjenje, koje sadrži 23 atoma ugljenika i ima molekulsku masu od 367,503 Da